The Effect of High Fat Diet on the Pharmacokinetics of AD16 Tablets in Healthy Chinese Adult Subjects
- Conditions
- Alzheimer Disease
- Interventions
- Other: fasted group（AD16 20mg）Other: high-fat diet group（AD16 20mg）
- Registration Number
- NCT05787041
- Lead Sponsor
- South China Center For Innovative Pharmaceuticals
- Brief Summary
The study was a single-center, randomized, open-access, two-crossover, single-dose study design with 16 subjects to evaluate the pharmacokinetics of a high-fat diet on a single dose of oral AD16 tablets in healthy Chinese adults and the safety of a single dose of oral AD16 tablets in healthy Chinese adults.
Compared with fasting administration, a high-fat diet reduced the rate of AD16 tablet absorption in healthy adult subjects and had no effect on overall exposure to AD16.
The elimination and distribution characteristics of AD16 in vivo were similar under the conditions of feeding and fasting administration.
A single dose of AD16 tablets after fasting and high fat diet showed good safety.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria:
- Healthy subjects were aged 18-45 years (including boundary values), male and female.
- Weight ≥50kg (male) or ≥45kg (female), and body mass index (BMI) of 19-24kg/m2 (including the boundary values at both ends).
- Have fully understood this study, voluntarily participated in it, and signed the Informed Consent.
- Subjects are able to communicate well with researchers and complete the study according to protocol.
- The subjects were deemed to be in good health based on physical examination, medical history, vital signs, electrocardiogram, chest X-ray, abdominal ultrasound, and laboratory tests.
- Subject (including partner) is willing to have no pregnancy plan for the next 30 days (female subject) or 90 days (male subject) and is willing to use effective contraception.
- Positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody or HIV antibody.
- The patient has symptoms or related history of any serious disease, including but not limited to heart, liver, kidney, or other acute or chronic digestive tract or respiratory tract diseases, as well as diseases of the blood, endocrine, neurological, psychiatric and other systems, or any other disease or physiological condition that can interfere with the study results.
- A history of postural hypotension with frequent episodes.
- A history of frequent nausea or vomiting due to any cause.
- Any clear history of drug or food allergies, especially allergies to ingredients similar to the drugs in this study.
- Have special dietary requirements and cannot comply with the uniform diet provided by the clinical research center.
- Previous drug abuse history or positive urine drug screening during screening period.
- Smokers who smoked more than 5 cigarettes a day in the 3 months before the test.
- Heavy drinkers or regular drinkers in the 6 months prior to the study screening, who drank more than 14 units of alcohol per week (1 unit of alcohol ≈360 mL beer or 45 mL 40% spirits or 150 mL wine) or had a positive alcohol breath test during the screening period.
- Excessive consumption of tea, coffee (more than 6 cups) and/or caffeinated beverages (more than 1L) per day.
- Take food or drink rich in xanthine, grapefruit or alcohol, caffeine (e.g., dragon fruit, mango, grapefruit, chocolate, coffee or tea) within 48 hours before administration.
- Surgical procedures, transfusions of blood or blood components in the month prior to study screening.
- Blood loss or donation of more than 400 mL in the 2 months prior to screening.
- Participated in other clinical studies and took experimental drugs within 3 months prior to study screening.
- Study participants who had received any medication in the 28 days prior to screening.
- Pregnant or lactating women or women who have had unprotected sex within 14 days.
- Those unable to complete the study for other reasons or deemed unsuitable for inclusion by the researcher.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Fasting group fasted group（AD16 20mg） A single dose of AD16 tablets was taken orally under fasting conditions High-fat diet group high-fat diet group（AD16 20mg） A single dose of AD16 tablets was taken orally after a high fat diet
- Primary Outcome Measures
Name Time Method Tmax of AD16 Up to Day 10 Time to reach the maximum (peak) plasma concentration following drug administration
Vd/F of AD16 Up to Day 10 Apparent volume of distribution after non-intravenous administration
MRT of AD16 Up to Day 10 Mean residence time(MRT)
λz of AD16 Up to Day 10 Terminal disposition rate constant/terminal rate constant
Cmax of AD16 Up to Day 10 Maximum (peak) plasma drug concentration
t1/2 of AD16 Up to Day 10 Elimination half-life (to be used in a one-compartment or noncompartmental model)
CL/F of AD16 Up to Day 10 CL/F is defined as the ratio of total clearance(CL) to bioavailability(F).
AUC 0-t of AD16 Up to Day 10 Area under the plasma concentration-time curve(AUC) from time zero to time t
AUC 0-∞ of AD16 Up to Day 10 Area under the plasma concentration-time curve(AUC) from time zero to infinity
- Secondary Outcome Measures
Name Time Method Number of participants with abnormal 12- Lead ECG readings day-7 to day-1 and days3 、10 abnormal 12- Lead ECG
Number of participants with abnormal physical examination findings day-7 to day-1 and day10 The skin, mucosa, lymph nodes, head, neck, chest, abdomen, spine/limbs and nervous system were observed at different time points before and after medication.
Adverse events day-7 to day 10 The number of adverse events
Number of participants with abnormal laboratory test results day-7 to day-1 and day10 Laboratory tests include blood routine, blood biochemistry, coagulation function and urine routine
Number of participants with abnormal vital signs day-7 to day3 and day7 to day10 vital signs include Pulse, blood pressure, body temperature and respiratory rate were observed at different time points before and after medication.
Concomitant medication Up to Day 10 Any concomitant medication
Serious adverse events day-7 to day 10 The number of serious adverse events
Trial Locations
- Locations (1)
The Central South University Xiang Ya Hospital
🇨🇳Changsha, China